Announcement • Jun 20
Algorae Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.024 million. Algorae Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.024 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,000,000
Price\Range: AUD 0.012
Transaction Features: Subsequent Direct Listing Announcement • Jun 16
Algorae Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 0.024 million. Algorae Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 0.024 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,000,000
Price\Range: AUD 0.012
Transaction Features: Subsequent Direct Listing Board Change • May 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. COO & Director David Gulland was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • May 01
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. COO & Director David Gulland was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 02
Algorae Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 1.0722 million. Algorae Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 1.0722 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 89,350,001
Price\Range: AUD 0.012
Transaction Features: Subsequent Direct Listing Board Change • Dec 24
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Bradley Latham was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Aug 18
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Non-executive Director Brad Dilkes is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Announcement • Aug 14
Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 02, 2025 Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 02, 2025. Announcement • Apr 03
Algorae Pharmaceuticals Limited Announces the Appointment of Vishal Shah as Chief Commercial Officer Algorae Pharmaceuticals Limited announced the appointment of seasoned pharmaceutical executive Vishal Shah as Chief Commercial Officer (`CCO'). With a distinguished career spanning over 20 years in pharmaceuticals, biotechnology, and healthcare, Mr. Shah will spearhead Algorae's commercial strategy to accelerate growth and expansion into complimentary pharmaceutical market segments. Mr. Shah joins Algorae from HPS Pharmacies, where he was responsible for shaping procurement strategy, driving revenue growth, and expanding market reach. At HPS Pharmacies, he was instrumental in accelerating business expansion, strengthening the Company's market position, and forging high-value partnerships. Prior to EBOS, Mr. Shah held senior leadership roles at Baxter Healthcare, including Associate Director of Pharmaceuticals for Asia-Pacific (`APAC') and Head of Pharmaceuticals Australia/New Zealand (`ANZ'). At Baxter, a global leader in medical technology and pharmaceuticals with a market capitalisation exceeding AUD 27 billion, he successfully led commercial strategy, executed major product launches, and oversaw growth initiatives that enhanced both revenue and earnings. His expertise spans navigating regulatory landscapes, establishing strategic alliances, and optimising commercial operations across international markets. Mr. Shah has a Pharmacy Degree, a Master's in Applied Science (Biotechnology), and an MBA from Western Sydney University, providing him with of the necessary scientific expertise and commercial acumen for his new role with Algorae. Announcement • Sep 06
Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 25, 2024 Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 25, 2024. New Risk • Jul 24
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$13.5m (US$8.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 8.8% per year over the past 5 years. Revenue is less than US$1m (AU$42k revenue, or US$28k). Market cap is less than US$10m (AU$13.5m market cap, or US$8.91m). Minor Risk Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Announcement • Jul 01
Algorae Pharmaceuticals Limited Announces Change of Company Secretary Algorae Pharmaceuticals Limited announced the appointment of Ms Jennifer Voon as Company Secretary, effective 1 July 2024. Ms Voon is a Chartered Accountant with over a decade's experience in financial services, with a focus on capital markets and compliance. Ms Maria Clemente of Automic Group will step down as Company Secretary effectively immediately. New Risk • Mar 19
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$15.0m (US$9.75m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 8.8% per year over the past 5 years. Revenue is less than US$1m (AU$42k revenue, or US$27k). Market cap is less than US$10m (AU$15.0m market cap, or US$9.75m). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding). New Risk • Jan 26
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$15.0m (US$9.84m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (AU$42k revenue, or US$28k). Market cap is less than US$10m (AU$15.0m market cap, or US$9.84m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding). Board Change • Jan 26
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Non-executive Director Brad Dilkes is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. New Risk • Aug 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.6m free cash flow). Earnings have declined by 2.9% per year over the past 5 years. Revenue is less than US$1m (AU$3.4k revenue, or US$2.2k). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (AU$22.9m market cap, or US$14.8m). Announcement • Jul 29
Living Cell Technologies Limited, Annual General Meeting, Sep 01, 2023 Living Cell Technologies Limited, Annual General Meeting, Sep 01, 2023, at 12:00 E. Australia Standard Time. Location: Thomson Geer Level 23, Rialto South Tower, 525 Collins Street, Melbourne Australia Agenda: To consider change of company name; to ratification of the issue of shares and options under the pre-Entitlement offer placement; to consider Ratification of the issue of Shares and Options under the Greenshoe Placement; to consider Ratification of the issue of Lead Manager Options; to consider and Approve of the issue of Lead Manager Options; to consider and Approve of the issue of Performance Shares to David Hainsworth; and to consider and Approve of the issue of Performance Shares to Brad Dilkes. Announcement • Jul 04
Living Cell Technologies Limited Announces Management Changes Living Cell Technologies Limited (LCT) announced that it has made the following changes to its board of directors: the appointment of Mr. Bradley Latham as a non-executive director of LCT, effective immediately, the appointment of Professor Carolyn Sue to the position of Chief Medical Officer (CMO) of NTCELL and simultaneous resignation from her non-executive director position, effective 1 July 2023. Mr. Latham is an accomplished and energetic businessperson with strong commercial acumen and extensive business experience. The majority of Mr. Latham's working career has been with Sydney Markets where he has worked his way through the ranks until appointed CEO of the group in 2006. Mr. Latham is experienced in all matters of business, including strategic planning, financial management, business development, operational management, and marketing of various successful brands, which has been instrumental in maintaining Sydney Markets' position as one of the premier privately owned markets in the world. Mr. Latham has a proven track record of business leadership and has a strong understanding of good corporate governance and risk management. He possesses an ability to identify and assess strategic growth opportunities, which is advantageous for LCT as it assesses various potential opportunities to expand and diversify its drug candidate profile. Mr. Latham holds a Master of Management from the University of New South Wales. Professor Carolyn Sue, MBBS, PhD, FRACP, is an internationally recognised clinician-scientist, a leader in Parkinson's disease and a medicine alum of UNSW who trained at Westmead Hospital and at Columbia University in the United States. Carolyn's experience, expertise and contributions to Parkinson's disease research have been widely recognised. She holds leadership roles in the Movement Disorder Society of Australia and New Zealand, and International Parkinson's disease and Movement Disorder Society, and is a Fellow of the Australian Academy of Medical Sciences. In 2019, Carolyn was awarded a member of the Order of Australia (AM) in recognition of her significant services to medicine. Professor Sue is leading a scientific review of the NTCELL clinical trial protocol and development plan in conjunction with a multi-disciplinary panel of scientific experts advising on various aspects of the NTCELL project. Professor Sue has resigned from her non-executive director position to focus all necessary attention on the role of CMO of NTCELL. Announcement • Jun 09
Living Cell Technologies Limited Appoints James A Mckenna as Chief Scientific Officer Living Cell Technologies Limited announced the appointment of Dr. James A Mckenna as Chief Scientific Officer (`CSO') of the Company. Dr. Mckenna is an experienced research scientist who holds a PhD in biochemistry and molecular biology from the University of Melbourne. Dr. Mckenna has been a full-time research scientist for 23 years, with experience in academic science, commercial drug development and intellectual property generation. Most recently, he held a leadership position at an ASX listed biotechnology company where he managed and was involved in teams to advance pre-clinical and clinical research and development (R&D) programs for the purpose of achieving US Food and Drug Administration (FDA) registration. Dr. Mckenna's appointment coincides with LCT's corporate strategy to expand and diversify the Company's development pipeline. The role of CSO will include: research pertaining to drug candidate development, arrangement of pre-clinical and clinical studies, and liaison with intellectual property attorneys and pharmaceutical regulators. Dr. Mckenna commences the role of CSO on 19 June 2023. Board Change • Nov 17
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director & Member of Medical Advisory Board Carolyn Sue was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 02
Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.003 loss in FY 2021) Full year 2022 results: AU$0.002 loss per share. Net loss: AU$1.96m (loss widened 34% from FY 2021). Recent Insider Transactions • Jun 11
Board Member recently bought AU$70k worth of stock On the 6th of June, Carolyn Sue bought around 10m shares on-market at roughly AU$0.007 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$77k more in shares than they have sold in the last 12 months. Reported Earnings • Sep 02
Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.002 loss in FY 2020) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: AU$268.2k (down 52% from FY 2020). Net loss: AU$1.46m (loss widened 51% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings. Recent Insider Transactions • Feb 17
Insider recently bought AU$182k worth of stock On the 12th of February, Jimmy Thomas bought around 8m shares on-market at roughly AU$0.023 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. 
